Allogeneic hematopoietic stem cell transplantation for myelofibrosis

than other patients. Results with unrelated donors were comparable with those with HLA-identical sibling transplants. Thus, allogeneic hematopoietic cell transplantation offers long-term relapse-free survival for patients with myelofibrosis. (Blood. 2003;102:3912-3918)

[1]  J. Cahn.  Clinical bone marrow and blood stem cell transplantation , 2004, Leukemia.

[2]  J. Hansen,et al.  Tissue typing in support of unrelated hematopoietic cell transplantation. , 2003, Tissue antigens.

[3]  W. Vainchenker,et al.  Prominent role of TGF-beta 1 in thrombopoietin-induced myelofibrosis in mice. , 2002, Blood.

[4]  J. Hansen,et al.  Impact of molecular histocompatibility typing on outcome of unrelated donor hematopoietic cell transplantation , 2002 .

[5]  H. Deeg,et al.  Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. , 2002, Blood.

[6]  A. Verma,et al.  Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasia. , 2002, Blood.

[7]  H. Deeg,et al.  Hematopoietic stem cell transplantation for advanced myelodysplastic syndrome after conditioning with busulfan and fractionated total body irradiation is associated with low relapse rate but considerable nonrelapse mortality. , 2002, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[8]  G. Barosi,et al.  Diagnostic and clinical relevance of the number of circulating CD34(+) cells in myelofibrosis with myeloid metaplasia. , 2001, Blood.

[9]  H. Deeg,et al.  Myeloablation and autologous peripheral blood stem cell rescue results in hematologic and clinical responses in patients with myeloid metaplasia with myelofibrosis. , 2001, Blood.

[10]  R. Mesa,et al.  Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia , 2001, British journal of haematology.

[11]  P. Thall,et al.  Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. , 2001, Blood.

[12]  H. Deeg,et al.  Haemopoietic stem cell transplantation for advanced polycythaemia vera or essential thrombocythaemia , 2001, British journal of haematology.

[13]  A. Tefferi.  Myelofibrosis with myeloid metaplasia. , 2000, The New England journal of medicine.

[14]  D. Nagorney,et al.  Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients. , 2000, Blood.

[15]  H. Deeg,et al.  Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. , 1999, Blood.

[16]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.

[17]  J. Slattery,et al.  Therapeutic monitoring of busulfan in hematopoietic stem cell transplantation. , 1998, Therapeutic drug monitoring.

[18]  C. Bueso-Ramos,et al.  Allogeneic marrow transplantation for myeloproliferative disorders other than chronic myelogenous leukemia: Review of forty cases , 1998, American journal of hematology.

[19]  H. Tilly,et al.  Allogeneic bone marrow transplantation for agnogenic myeloid metaplasia , 1997 .

[20]  R. Storb,et al.  Allogeneic marrow transplantation for primary myelofibrosis and myelofibrosis secondary to polycythaemia vera or essential thrombocytosis , 1997, British journal of haematology.

[21]  H. Deeg,et al.  Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. , 1997, Blood.

[22]  G. Longton,et al.  Association of HLA-C disparity with graft failure after marrow transplantation from unrelated donors. , 1997, Blood.

[23]  J. Laszlo,et al.  Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment. , 1997, Seminars in hematology.

[24]  P. Morel,et al.  Prognostic factors in agnogenic myeloid metaplasia: a report on 195 cases with a new scoring system. , 1996, Blood.

[25]  J. Hansen,et al.  A comprehensive approach for typing the alleles of the HLA-B locus by automated sequencing. , 1995, Tissue antigens.

[26]  Gruppo Italiano Studio Policitemia*.  Polycythemia Vera: The Natural History of 1213 Patients Followed for 20 Years , 1995, Annals of Internal Medicine.

[27]  R. Clift.  Marrow transplantation for chronic myeloid leukemia. , 1995, Cancer treatment and research.

[28]  E. Feliú,et al.  Life expectancy of patients with chronic nonleukemic myeloproliferative disorders , 1991, Cancer.

[29]  S. Pileri,et al.  Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients , 1990, British journal of haematology.

[30]  H. Hasselbalch,et al.  Prognostic factors in idiopathic myelofibrosis: A simple scoring system with prognostic significance , 1990, European journal of haematology.

[31]  S. Lewis,et al.  ALLOGENEIC BONE MARROW TRANSPLANTATION FOR PRIMARY MYELOFIBROSIS , 1989, British journal of haematology.

[32]  K. Sullivan,et al.  Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. , 1981, Blood.

[33]  M. Block.  Agnogenic myeloid metaplasia. , 1974, Revista brasileira de pesquisas medicas e biologicas.